Device Trial Radar · NCT03459365
Euflexxa for the Treatment of Osteoarthritis
Last checked: Nov 19, 2026Latest source record: Sep 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jul 9, 2018
Primary completion
Sep 30, 2021
Study completion Oct 31, 2021
Sponsor
- Lead sponsor
- The Cleveland ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 8, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The effect of Euflexxa therapy for knee osteoarthritis on levels of inflammatory and degenerative synovial fluid bio-markers in patients with knee osteoarthritis
Conditions
- Osteo Arthritis Knee
Interventions
EuflexxaDevice
Aspirations performed before each injection and at six weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Hyaluronate ConcentrationTime frame: Baseline to 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cleveland Clinic
Cleveland, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.